Ionis (IONS) Q2 Revenue Soars 101%

Ionis Pharmaceuticals (NASDAQ:IONS), a biotechnology company focused on RNA-targeted therapeutics, reported its second quarter 2025 earnings on July 30, 2025. The headline news was a substantial beat on both GAAP revenue and non-GAAP earnings compared to Wall Street estimates. GAAP revenue reached $452 million, well above the $298.3 million analyst consensus. Ionis also raised its full-year 2025 revenue guidance by $100 million, driven by early commercial momentum for new products and a significant one-time licensing payment. Overall, the quarter showed major progress across commercial launches and strategic partnerships, though the sharp jump in profit was tied to nonrecurring events.Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Ionis is a biotechnology company developing medicines based on RNA-targeted technology known as antisense. This technology allows Ionis to design drugs that can specifically block or alter the production of disease-related proteins at the genetic messaging (RNA) level. The approach enables it to address diseases that are difficult to treat using conventional drugs.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool